Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.15 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -20.5 | |||||
3-Year EPS without NRI Growth Rate | -27.2 | |||||
3-Year FCF Growth Rate | -2.6 | |||||
3-Year Book Growth Rate | 0.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.31 | |||||
9-Day RSI | 51.27 | |||||
14-Day RSI | 49.28 | |||||
6-1 Month Momentum % | 41.25 | |||||
12-1 Month Momentum % | 22.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.44 | |||||
Quick Ratio | 5.44 | |||||
Cash Ratio | 3.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.2 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -78.73 | |||||
ROA % | -67.71 | |||||
ROIC % | -495.93 | |||||
ROC (Joel Greenblatt) % | -1199.75 | |||||
ROCE % | -85.67 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.71 | |||||
Price-to-Tangible-Book | 4.89 | |||||
EV-to-EBIT | -3.48 | |||||
EV-to-EBITDA | -3.5 | |||||
EV-to-Forward-Revenue | 42.57 | |||||
EV-to-FCF | -4.54 | |||||
Price-to-Net-Current-Asset-Value | 5.51 | |||||
Price-to-Net-Cash | 8.65 | |||||
Earnings Yield (Greenblatt) % | -28.72 | |||||
FCF Yield % | -19.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.9 | ||
Beta | -0.08 | ||
Volatility % | 60.81 | ||
14-Day RSI | 49.28 | ||
14-Day ATR (€) | 0.274651 | ||
20-Day SMA (€) | 10.6675 | ||
12-1 Month Momentum % | 22.16 | ||
52-Week Range (€) | 6.9 - 20.2 | ||
Shares Outstanding (Mil) | 42.19 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
KalVista Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(FRA:4XC1)'s stock price today?
When is next earnings date of KalVista Pharmaceuticals Inc(FRA:4XC1)?
Does KalVista Pharmaceuticals Inc(FRA:4XC1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |